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Introduction
Despite the success of HAART in the treatment 
of HIV infection, treatment failure still occurs as a 
result of poor tolerability, lack of adherence, inade-
quate plasma drug level and the onset of drug resis-
tant viruses. Such issues may limit options for further 
therapy, particularly for patients who experienced 
triple-drug class virologic failure and who may be at 
increased risk of death (3 year mortality rate, 15%) (1, 
2). Therefore, newer agents with activity against drug-
resistant HIV-1 are needed.
Tipranavir is the first of a new class of nonpep-
tidic PI (NPPI) that has demonstrated potent inhibi-
tory activity against clinical HIV-1 and HIV-2 isolates 
in vitro and in vivo (3-5). TPV has a different struc-
ture from peptidic PIs, and therefore has a different 
susceptibility/resistance profile when compared with 
other PIs. Studies of clinical isolates have shown that 
TPV has activity against HIV isolates resistant to cur-
rently available PIs and that 16 to 20 protease gene 
mutations/polymorphisms may be required to confer 
reduced susceptibility to TPV (6, 7). Additionally, in 
the randomized evaluation of strategic intervention 
in multi-drug resistant patients with tipranavir (RE-
SIST-1 and RESIST-2) studies, the efficacy of tipra-
navir/ritonavir in 1509 highly treatment-experienced 
HIV-positive patients is being assessed over 96 weeks. 
The results showed the durable superiority of TPV/r 
compared with other boosted-PI regimens in achiev-
ing viral load declines, in delaying treatment failure 
and increasing the CD4-positive T-lymphocyte (CD4) 
count. In addition, these studies showed that the safe-
ty profile of TPV/r was similar to that of the other 
ritonavir-boosted PI, despite the use of a larger daily 
dose of ritonavir in patients receiving tipranavir. Di-
arrhoea, nausea and fatigue were the most common 
clinical adverse events reported in both treatment 
AbstrAct
The Italian Tipranavir EUP/EAP study was an observational study involving nine Italian centres that enrolled three class drug-
experienced patients who consecutively entered the EUP/EAP TPV programs. The Cox model performed to assess the risk corre-
lates of interrupting TPV included sex, age, HIV risk factors, HBV/HCV status, use of T20,CD4, HIV-RNA, ALT, γ-GT, cholesterol, 
triglycerides, glucose levels determination before starting TPV. The study enrolled 175 patients followed up for a median time of 
30 weeks (range 3-68). TPV was interrupted by 46 patients (16 for intolerance, 14 for immuno-virological failure, four for disease 
progression – including two deceased – 12 for patient decision). The factors independently associated with treatment interruption 
for any cause were previous ART duration (OR 1.18, 95%CI 1.03-1.35, p=0.016 per each additional year) and γ-GT BL (grade 2 vs 
0: OR 6.31, 95%CI 2.49-16.4, p< 0.0001). The γ-GT BL median level in the 16 patients who interrupted TPV for intolerance was 
122 IU/L (range: 11-352). Both γ-GT and ALT were significantly increased at interruption compared to BL (p=0.041 and p=0.016 
respectively, Wilcoxon test). A transient protective effect against γ-GT and TG increase was observed in patients receiving T20 
with TPV (p=0.034 and p=0.027 respectively at week 12 in a Cox model assessing the risk of increasing one toxicity grade). γ-GT 
level seems to be relevant and more sensitive than ALT/AST level or HBV/HCV status in predicting the risk of TPV interruption. 
Unreported alcohol abuse could be considered a potential cofactor limiting the effectiveness and safety of TPV/RTV treatment. 
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arms. Hepatic and lipid-related adverse events oc-
curred at a greater frequency in the tipranavir/rito-
navir arm, but were rarely a cause of discontinuation 
(8-11). 
Considering the important role of this drug in the 
achievement of effective viral suppression in patients 
infected with multidrug-resistant strains who have 
limited treatment options, we analysed the causes of 
TPV discontinuation and the factors influencing TPV 
interruption in a cohort of Italian patients enrolled in 
the tipranavir expanded access program/emergency 
use program (EAP/EUP programs).  
Methods
Patients were HIV-infected male and female 
adults enrolled in the tipranavir EAP/EUP programs 
(Boehringer Ingelheim Trial No 1182.16) in nine Ital-
ian centres. The study design was open label and non-
randomised. Patients were required to be triple anti-
viral class experienced, including at least two previ-
ous PI-based regimens, who had failed or who were 
intolerant to other HIV-1 treatments. There were 
no restrictions on CD4 count or viral load. Patients 
with hepatitis were not excluded, provided they were 
stable and with no greater than grade 2 liver func-
tion test abnormalities at baseline. The study was 
designed and monitored in accordance with good 
clinical practices. Local institutional review boards 
of participating centres approved both EAP and EUP 
studies. Written informed consent was obtained from 
all study participants. Enrolled patients received tip-
ranavir (TPV) 500 mg co-administrated with ritona-
vir (RTV) 200 mg, twice daily (b.i.d.) orally, plus at 
least two other NRTI/N(t)RTI and/or T-20.
The aims of the study were to allow for an early ac-
cess to tipranavir and to evaluate the safety and toler-
ability to the drug. Safety evaluations were conducted 
after TPV/r initiation at one, two, three months, and 
every three months thereafter with clinical and labo-
ratory valuations. 
 
Differences between patients treated or not with T20 
were tested by means of Mann-Whitney non para-
metric test and chi-square test. When evaluating the 
trend of hepatic and lipid parameters, Wilcoxon non 
parametric test was applied. Survival free from treat-
ment interruption by any cause and by specific cause 
was analysed utilizing Kaplan-Meier methods and 
Cox regression models. Estimates of crude and ad-
justed relative risks were shown as hazard ratios (HR 
and AHR) with 95% confidence interval. All covariates 
taken into account in the analyses of risks of interrup-
tion by any cause and by immuno-virological failure 
were forced to enter the final regression model. Due 
to the low number of interruptions by intolerance, a 
step-forward selection was applied in the adjusted re-
gression model. The software statistical package used 
for all the analyses was SPSS 14.1 (SPSS Inc. Head-
quarters, Chicago, Illinois).
Results
175 patients were enrolled in the study; T-20 treat-
ment was associated in 89 (50.9%) of these subjects. 
Most patients were male, with a median age of 41 
years. The distribution of risk factors was intravenous 
drug users or ex-intravenous drug users 38.3%, hetero-
sexuals 36% and homosexuals 21.7%. 18.3% of patients 
were alcohol abusers; 93.7% of patients were HBsAg 
negative and 62.9% were HCV-Ab negative (Table 1). 
Viro-immunologic characteristics and previous 
drug experience at baseline are summarized in Table 
2. Median baseline CD4 cell count was 137 cell/mmc; 
median HIV-RNA was 4.7 log/cp. Patients were ART 
multiexperienced (median ART duration 10.2 years) 
and heavily PI experienced (median of 5 PI used in the 
previous ART treatments).
A summary of hepatic and metabolic parameters 
at baseline is presented in Table 3. Median AST and 
ALT was 34 U/L and 39 U/L, respectively; the median 
of gamma-GT was 57 U/L. Regarding the lipid panel 
the medians of total cholesterol, HDL cholesterol and 
triglycerides were 164 mg/dL, 36 mg/dL and 196 mg/
dL, respectively.
 
Patients demonstrated a high treatment response 
rate: HIV-RNA was <50 cp/mL in 41.4%, 50.9% and 
37.4% at six, 12, 24 months of treatment with tipra-
navir, respectively. A superior treatment response 
was reported with use of enfuvirtide: HIV-RNA un-
detectable in 42.6% with T-20 versus 40.4% without 
T-20, 56.3% versus 42.9%, 40.0% versus 33.3% at six, 
12, 24 months of therapy; however, the difference be-
tween the two groups was not statistically significant 
(p=0.811, p=0.340 and p=0.520, respectively). The 
higher virologic response achieved 
was reflected in the observed im-
munologic response. There was 
an increase in CD4 cell counts at 
all time points, relative to base-
line: medians of CD4 cell count at 
month six, 12 and 24 were 193 cell/
mmc, 199 cell/mmc, 287 cell/mmc, 
respectively. Also in the analysis of 
CD4 cell counts use of T-20 was 
associated with higher response: 
median in CD4 cell count from 123 
cell/mmc at baseline to 314 cell/
mmc at month 24 with enfuvirtide 
use, and from 155 cell/mmc at 
baseline to 265 cell/mmc at month 
24 without enfuvirtide; also in this 
analysis the difference between the 
two groups was not statistically sig-
Table 1: Population characteristics at baseline.
Male Female
Age (years)
Median 41.65 39.79
Range (min-max) 22.04-65.64 18.20-47.11
Risk factors (%)
IVDUs/past IVDUs 43.3 17.6
Heterosexual 26.2 76.5
Homosexual 27.0 -
Alcohol (%) 19.1 14.7
AIDS diagnosis (%) 53.2 35.3
HBsAg + (%) 5.7 2.9
HCV-Ab+ (%) 37.6 29.4
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nificant (p=0.576, p=0.273 and p=0.659, respectively).
 
Hepatic and lipid parameters trend showed that AST 
and ALT medians did not significantly increase during 
tipranavir treatment, while gamma-GT increased at all 
time points (median gamma-GT 57 U/L, 95 U/L, 113 
U/L, 136 U/L, 137 U/L, 171 U/L, 119 U/L at months 
one, three, six, nine, 12 and 24, respectively). Medians 
of total cholesterol, HDL cholesterol and triglycerides 
in our cohort of patients also failed to show a significant 
increase during therapy.
 
This study also analysed the causes of tipranavir inter-
ruption and the factors that may be involved in treatment 
discontinuation. At 12 months of therapy 26.3% (46 sub-
jects) of patients interrupted tipranavir, while at month 
24 63.5% (80 subjects) of patients interrupted therapy. 
The most important cause of tipranavir discontinua-
tion was viro-immunologic failure (30.4% and 42.5% at 
months 12 and 24, respectively), followed by intolerance 
(34.8% and 20.0% at months 12 and 24, respectively) and 
lack of adherence (6.5% and 6.3% at months 12 and 24). 
A multivariate analysis was performed to evalu-
ate factors that could influence TPV interruption. 
At month 12, gamma-GT was the only factor influenc-
ing treatment interruption for any cause, with a p=0.047 
and p=0.002 for grade 0 and grade 2 of gamma-GT, 
respectively (Table 4). At month 24, level of 
Table 4: Factors influencing TPV interruption (any cause); Multivariate analysis (Cox model).
HR 95%CI p
ART duration (per additional year) 1.18 1.03-1.35 0.016
g-GT  grade 1 2.06 0.84-5.09 0.116
grade 2 6.37 2.48-16.4 0.000
grade 3 6.42 1.00-41.3 0.050
ALT grade 1 2.09 0.81-5.31 0.127
grade 2 1.23 0.34-4.46 0.749
grade 3 2.34 0.19-28.9 0.507
Glucose > 100mg/dL 1.48 0.52-4.21 0.466
Tg 150-199 mg/dL 0.45 0.12-1.72 0.242
200-499 mg/dL 0.69 0.30-1.58 0.386
> 500 mg/dL 1.16 0.30-4.41 0.833
Chol 200-239 mg/dL 1.50 0.49-4.63 0.479
>240 mg/dL 1.38 0.38-5.09 0.626
Table 2: Viro-immunologic characteristics.
Median Range (min-max)
CD4 baseline (cell/µL) 137 2-903
CD4 nadir    (cell/µL) 80 1-540
HIV-RNA (log/copies)* 4.7 1.7-6.5
ART duration (yrs) 10.2 3.5-18.0
NRTI used 6 2-7
NNRTI used 1 0-3
PI used 5 1-7
PI mutations 8 2-12
* at baseline
Table 3: Metabolic parameters at baseline.
Median Range (min-max)
ALT (UI/L) 39 8-259
AST (UI/L) 34 8-227
g-GT (UI/L) 57 7-578
Total cholesterol (mg/dL) 164 71-408
HDL cholesterol (mg/dL) 36 11-128
Triglycerides (mg/dL) 196 32-1521
Glucose (mg/dL) 88 48-2523
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gamma-GT was not a significant covariate for 
treatment interruption due to failure. Lastly, a 
Wilcoxon test was performed to study the trend of 
hepatic and lipid parameters at baseline and at TPV 
interruption due to intolerance. We did not 
see a significant increase in lipid parameters 
(Figure 1), whereas there was a significant in-
crease in median values of hepatic parameters 
(Figure 2). 
Discussion
Current antiretroviral regimens for HIV-in-
fected subjects have improved the durability of 
Figure 1: Hepatic parameters (median values and range) at baseline and at TPV interruption due to intolerance. 
Figure 2: Metabolic parameters (median values and range) at baseline and at TPV interruption due to intolerance.
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treatment response. However, some patients ex-
perience viral load rebound, develop resistance to 
ARV drugs and CD4 cell count decline. For PI-ex-
perienced patients failing their therapy, treatment 
options that can offer a sustained clinical benefit 
may be limited. In this context the introduction 
of tipranavir into clinical practice enhances the 
choice of PIs for inclusion in second- and third-
line regimens: tipranavir-ritonavir given the ro-
bustness of its genetic barrier to resistance, and 
represents an important option for patients in-
fected with multidrug-resistant HIV strains who 
need a potent drug to build an affective treatment 
regimen (12, 13).
Complete virological suppression is the only 
proven way to achieve long-term clinical benefits. 
Therefore, the aim of therapy for all HIV-infected 
patients is to reach the virologic and immunologic 
response regardless of whether a patient is treat-
ment-naïve or treatment-experienced. The results 
of this study confirm that tipranavir/ritonavir can 
achieve virologic suppression and improve im-
munological response in highly experienced and 
heavily PI-experienced patients, who showed low 
levels of CD4 cell count and HIV-RNA not sup-
pressed at baseline. In our study the concomitant 
use of enfuvirtide was associated with a superior 
treatment response, both in virologic and immu-
nologic parameters, although the results were not 
statistically significant, probably due to the low 
number of patients. The role of enfuvirtide in the 
efficacy of a therapy regimen containing tiprana-
vir/ritonavir deserves further investigation. 
Despite the efficacy of tipranavir/ritonavir 
(7-11), the use of this drug is limited in clini-
cal practice by hepatic and lipid-related adverse 
events and by the early interruption of the treat-
ment. Considering the important role of this drug 
in the achievement of effective viral suppression 
and immunological improvement, we analysed 
the causes of TPV discontinuation and the factors 
influencing TPV interruption. 
The results of this study show that tipranavir 
is safe and relatively well tolerated in this mul-
tiple PI-experienced patient population: hepatic 
and lipid parameters do not significantly increase 
during therapy and are rarely the cause of study 
discontinuation, also in patients coinfected with 
viral hepatitis or alcohol abusers. The most com-
mon clinically significant laboratory abnormality 
was increased gamma-GT.
This study also analysed the causes of tipra-
navir interruption and the factors that may be 
involved in treatment discontinuation. The most 
important cause of TPV interruption in our co-
hort of patients was viro-immunologic failure, 
most probably due to the category of patients, 
more than intolerance. 
Interestingly, in our analysis gamma-GT seems 
to be relevant in predicting the risk of TPV inter-
ruption within the first year of therapy: gamma-
GT correlated per se with tipranavir interruption 
and high levels of gamma-GT during therapy 
predicted the risk of drug discontinuation in the 
early period of treatment, whereas gamma-GT 
did not influence drug interruption after the first 
year of tipranavir therapy. This finding suggests 
that clinicians could pay attention to the levels 
of gamma-GT more than AST and ALT level, or 
lipid parameters, or HBV/HCV status when they 
start therapy containing tipranavir/ritonavir.     
One limitation of this study is the low number 
of trial participants. Although the patient popu-
lation is sufficient to demonstrate the efficacy of 
the treatment containing tipranavir/ritonavir, it 
may not provide meaningful data on the safety 
of this therapy and factors that can predict drug 
interruption. In this analysis, the role of enfu-
virtide in the tolerability of a therapy regimen 
containing tipranavir/ritonavir deserves further 
investigation. 
 
In conclusion, although these findings are lim-
ited by the small number of patients, they should 
provide clinicians with evidence that the com-
bination of tipranavir/ritonavir with an active 
optimised background regimen in antiretroviral-
experienced patients plays an important role in 
the achievement of sustained viral suppression 
and immunological improvement- Moreover, this 
treatment proved safe in our cohort of patients 
with no significant increase in hepatic and lipid 
parameters, and relatively well tolerated, with a 
low number of patients interrupting therapy due 
to intolerance. 
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